바이오의약품 접근성 확대 방안

• 영문명: Measures to Expand Access to Biopharmaceuticals: Focusing on European and North American Cases
• 발행기관: 한국보건사회약료경영학회
• 저자명: 김유진 임예지 최예진 배승진
• 간행물 정보: 『한국보건사회약료경영학회지』제11권 제2호, 63~70쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2023.11.30

영문 초록

Backgrounds: Biopharmaceutical market is the fastest growing market in the pharmaceutical industry. However, since better drugs are sold at higher price, these drugs are less accessible by the patient population. Methods: For this study, literatures from 2018 to 2023 were searched. Pubmed (MEDLINE), Web of Science Core Collection, and Google scholar were selected for electronic databases. As a keyword ('biosimilar' OR 'biosimilars') AND ('regulatory' OR 'guideline'', 'ICH' OR 'FDA' OR 'EMA') were used, and the search was conducted by specifying that the key words should be included in the title and abstract. Result: Efforts of regulators such as EMA(European Medicines Agency) and FDA (U.S. Food and Drug Administration) - reducing approval requirements by omitting animal testing and clinical trials and promoting market penetration of biosimilars - are needed to expand market entry of biopharmaceuticals. Furthermore, expanding the indication of biosimilars through extrapolation and approving biosimilars' substitution and switching can also improve accessibility of biopharmaceuticals. Lastly, the expansion of biosimilar awareness and the prevention of illegal transactions will also contribute to the improvement of accessibility of biopharmaceuticals. Conclusion: The significance of this study is that it examines how the use of biosimilars can be promoted and ultimately the accessibility of biopharmaceuticals can be expanded, focusing on specific cases in Europe and the United States.

목차

서 론

연구 방법

연구 결과

고찰 및 결론

감사의 말씀

참고문헌

키워드

biologics biosimilar biopharmaceuticals accessibility